Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
Clinical trial NCT07166367 · TERMINATED
Trial details
- NCT number
- NCT07166367
- Sponsor
- National Cancer Centre, Singapore
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-11
- Primary completion
- 2020-01-14
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.